A share price of Akero Therapeutics Inc [AKRO] is currently trading at $53.88, down -0.37%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AKRO shares have gain 16.88% over the last week, with a monthly amount glided 19.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on August 04, 2025, and set its price target to $76. On January 30, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $63 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $72 on January 27, 2025. Citigroup initiated its recommendation with a Buy and recommended $65 as its price target on November 18, 2024. In a note dated September 19, 2023, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $69 on this stock.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.34 and $58.40. Currently, Wall Street analysts expect the stock to reach $54.67 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $53.88 at the most recent close of the market. An investor can expect a potential return of 1.47% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.25% with Operating Profit Margin at -80370.75%, Pretax Profit Margin comes in at -70989.75%, and Net Profit Margin reading is -70989.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.32 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 12.66. Also, the Quick Ratio is 12.66, while the Cash Ratio stands at 3.65.
Transactions by insiders
Recent insider trading involved Rolph Timothy, Chief Scientific Officer, that happened on Oct 07 ’25 when 12500.0 shares were sold. Officer, Timothy Rolph completed a deal on Oct 07 ’25 to buy 56369.0 shares. Meanwhile, Chief Operating Officer Young Jonathan sold 12500.0 shares on Oct 01 ’25.
